LATS1 and breast carcinoma: During the treatments with veliparib and ponatinib, SNVs occurred on or near LATS1 (a core component of Hippo-YAP pathway), MGMT (related to DNA damage), IL17RB (related to NF-κB signaling) and APCDD1L (related to wnt signaling), all of which are known to be related to breast cancer.